Logo

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

Share this

BMS Reports Pooled Five Year Results of Opdivo (nivolumab) in Two P-III Studies for Advanced Non-Small Cell Lung Cancer

Shots:

  • The pooled analysis of the two P-III CheckMate -017 and -057 studies involves assessing of Opdivo (3 mg/kg- q2w) vs Docetaxel (75 mg/m2- q3w) in 854 patients in a ratio (1:1) with previously treated NSCLC across both squamous and non-squamous histologies
  • The P-III studies result: @5yrs. OS (13.4% vs 2.6%); patients continued to see response (32.2% vs 0%); m-DoR (19.9 vs 5.6 mos.); no new safety signals with extended follow-up
  • Opdivo is a PD-1 immune checkpoint inhibitor- harnessing the body’s own immune system to restore anti-tumor immune response and is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world

Click here to­ read full press release/ article

Ref: BMS | Image: BMS


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions